US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bexmarilimab shows promising anti-tumour activity

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab monotherapy shows promising anti-tumour activity in multiple advanced solid tumours · Headline data reported from patients enrolled in completed Part I and ongoing Part II of MATINS study · Strongest disease control rate (DCR) of 31% seen in cutaneous melanoma, gastric cancer and cholangiocarcinoma patients · 100% six-month survival rate observed in DCR patients compared with 31.1 % for non-DCR patients · Equivalent prior treatment durations for DCR and non-DCR patients suggests DCR with bexmarilimab is

Bexmarilimab (Clevegen) development update

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab (Clevegen) development update · Significant survival benefit observed in patients responding to bexmarilimab treatment with risk of death reduced by 88% · Gastric cancer becomes sixth tumour cohort to show early signs of clinical efficacy · Data monitoring committee recommends dose escalation expansion in all six cohort types besides ongoing colorectal cancer Company announcement, 22 March 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON),

Bexmarilimab (Clevegen) development update

· Accumulating MATINS data build foundation for further clinical development · Five patient cohorts in MATINS study Part II already fully recruited · Higher frequency of dosing introduced to investigate potential for enhanced clinical responses · Three new trials will study bexmarilimab treatment in neoadjuvant setting, in combination with PD(L)-1 checkpoint inhibitor and in haematological malignanciesCompany announcement, 23 November 2020 at 9.00 AM (EET)  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company,

MATINS trial data presented at ESMO

Data from completed Part I of bexmarilimab MATINS trial presented at ESMO Virtual Congress 2020TURKU – FINLAND, 18 September 2020 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today announces details from an oral presentation being held at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, showcasing data from the Company’s ongoing MATINS trial to the scientific community. The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of bexmarilimab, Faron's wholly-owned novel

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe